Chiome Bioscience Inc. (TYO:4583)
Japan · Delayed Price · Currency is JPY 74.00
-2.00 (-2.63%)
Jun 3, 2026, 3:30 PM JST
Chiome Bioscience Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 593.29 | 780.81 | 682.46 | 630.82 | 712.93 | |
Revenue Growth (YoY) | -24.02% | 14.41% | 8.19% | -11.52% | 48.26% |
Cost of Revenue | 237.71 | 347.96 | 283.87 | 281.96 | 290.47 |
Gross Profit | 355.58 | 432.85 | 398.6 | 348.86 | 422.46 |
Selling, General & Admin | 558.82 | 526.98 | 551.86 | 471.9 | 444.59 |
Research & Development | 776.54 | 936.74 | 1,052 | 1,136 | 1,312 |
Operating Expenses | 1,335 | 1,464 | 1,604 | 1,608 | 1,757 |
Operating Income | -979.77 | -1,031 | -1,205 | -1,259 | -1,334 |
Interest Expense | -3.16 | -2.87 | -2.07 | -1.32 | -1.32 |
Interest & Investment Income | 2.46 | 0.22 | 0.02 | 0.02 | 0.03 |
Currency Exchange Gain (Loss) | -0.14 | 0.92 | 0.51 | -0.57 | 6.63 |
Other Non Operating Income (Expenses) | -8.52 | 13.39 | -10.54 | 16.69 | -0.33 |
EBT Excluding Unusual Items | -989.13 | -1,019 | -1,217 | -1,244 | -1,329 |
Gain (Loss) on Sale of Investments | - | - | - | - | -150 |
Other Unusual Items | 9.59 | 1.67 | 2.23 | 5.98 | 12.91 |
Pretax Income | -979.54 | -1,018 | -1,215 | -1,238 | -1,466 |
Income Tax Expense | 3.24 | 3.24 | 5.01 | 5.01 | 13.49 |
Earnings From Continuing Operations | -982.78 | -1,021 | -1,220 | -1,243 | -1,480 |
Net Income | -982.78 | -1,021 | -1,220 | -1,243 | -1,480 |
Net Income to Common | -982.78 | -1,021 | -1,220 | -1,243 | -1,480 |
Shares Outstanding (Basic) | 68 | 58 | 50 | 44 | 40 |
Shares Outstanding (Diluted) | 68 | 58 | 50 | 44 | 40 |
Shares Change (YoY) | 16.65% | 17.48% | 12.64% | 9.20% | 12.26% |
EPS (Basic) | -14.47 | -17.54 | -24.62 | -28.26 | -36.74 |
EPS (Diluted) | -14.47 | -17.54 | -24.62 | -28.26 | -36.74 |
Free Cash Flow | -976.07 | -1,001 | -1,069 | -1,191 | -1,131 |
Free Cash Flow Per Share | -14.38 | -17.19 | -21.58 | -27.08 | -28.09 |
Gross Margin | 59.93% | 55.44% | 58.40% | 55.30% | 59.26% |
Operating Margin | -165.14% | -132.03% | -176.59% | -199.53% | -187.16% |
Profit Margin | -165.65% | -130.73% | -178.77% | -197.03% | -207.58% |
Free Cash Flow Margin | -164.52% | -128.16% | -156.67% | -188.81% | -158.68% |
EBITDA | -976.03 | -1,030 | -1,204 | -1,257 | -1,331 |
EBITDA Margin | -164.51% | -131.88% | -176.41% | -199.29% | -186.75% |
D&A For EBITDA | 3.74 | 1.17 | 1.2 | 1.48 | 2.96 |
EBIT | -979.77 | -1,031 | -1,205 | -1,259 | -1,334 |
EBIT Margin | -165.14% | -132.03% | -176.59% | -199.53% | -187.16% |